Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasacthin versus Synacthen for diagnosis of adrenal insufficiency
ISRCTN26461337Phase 3Active, not recruiting
- Sponsor
- Sheffield Children's Hospital
- Start
- Feb 2025
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, open-label trial of Nasacthin and tetracosactide hexaacetate in hypoadrenocorticism (2 arms), sponsored by Sheffield Children's Hospital. Primary endpoint: Positive percent agreement of Nasacthin test at 30 minutes. Started Feb 2025; status: active, not recruiting.
02
Drugs
Nasacthintetracosactide hexaacetate
03
Conditions
hypoadrenocorticism
Beyond the preview
Go deeper on ISRCTN26461337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26461337.